Skip to main content
Midas Edge

BIONOMICS LIMITEDFI

For the period ended Sep 30, 2024. Filed Nov 14, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 14, 2024

NEUP$2.78+0.4%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statement of Changes in Shareholders' Equity

Condensed Consolidated State ment of Changes in Shareholders' Equity (Unaudited)

Stock · Additional · AccumulatedOther · Total
Ordinary Shares · Subscription · Paid-In · Comprehensive · Accumulated · Shareholders'
Shares · Amount · Receivable · Capital · Loss · Deficit · Equity
Balance at June 30, 20242,384,539,964$-$-$198,481,038$(3,013,595)$(177,977,071)$17,490,372
Exercise of pre-funded ADS warrants733,122,900--409--409
Share issue costs---(227,747)--(227,747)
Share-based compensation---26,736--26,736
Other comprehensive income----585,381-585,381
Net loss-----(804,787)(804,787)
Balance at September 30, 20243,117,662,864$-$-$198,280,436$(2,428,214)$(178,781,858)$17,070,364
Balance at June 30, 20231,468,735,424$-$-$187,554,251$(3,058,783)$(162,484,905)$22,010,563
Issuance of ADS shares, net of issuance costs of $0.5 million378,155,880-(5,648,976)6,261,514--612,538
Share-based compensation---140,448--140,448
Other comprehensive loss----(63,469)-(63,469)
Net loss-----(5,472,568)(5,472,568)
Balance at September 30, 20231,846,891,304$-$(5,648,976)$193,956,213$(3,122,252)$(167,957,473)$17,227,512
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.